Immuron Ltd. (OTC: IMROY) is an Australian microbiome company focused on developing and commercializing oral immunotherapeutics for treating stomach diseases. Immuron has a unique and safe technology platform that allows for faster healing. The company currently markets Travelan® for the prevention of traveler’s’ diarrhea, its lead product candidate IMM-124E is in phase 2 clinical trials for NASH and ASH, and it has a preclinical immunotherapy pipeline targeting immune-related diseases with unmet needs. For more information, visit the company’s website at www.immuron.com/